睿智医药回复向特定对象发行股票审核问询函，申请文件同步更新

Core Viewpoint - Ruizhi Pharmaceutical has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a private placement of shares, indicating ongoing regulatory scrutiny and the need for further approvals before proceeding with the issuance [1]. Group 1: Company Actions - The company, along with relevant intermediaries, has carefully studied the issues raised in the inquiry letter and has provided responses, updating the prospectus and other application documents, which were disclosed on October 13 [1]. - The issuance of shares is contingent upon approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, highlighting the regulatory hurdles the company faces [1]. Group 2: Regulatory Environment - The final decision on whether the application will be approved and the timeline for such decisions remain uncertain, indicating potential delays in the company's fundraising efforts [1]. - The company has committed to timely information disclosure based on the progress of the application, emphasizing its obligation to keep investors informed about developments [1].